Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
Eun Jin Kim, Sun Ha Choi, Jae Seok Park, Yong Shik Kwon, Jaehee Lee, Yeonjae Kim, Shin Yup Lee, Eun Young Choi
Abstract
=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.
Topics & Concepts
MedicineOdds ratioCobicistatConfidence intervalDarunavirInternal medicinePropensity score matchingIntensive care unitVirologyHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchPharmacological Receptor Mechanisms and Effects